DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Arbekacin is an investigational drug.
There have been 5 clinical trials for Arbekacin. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Communicable Diseases, Pneumonia, Bacterial, and Pneumonia. The leading clinical trial sponsors are Meiji Seika Pharma Co., Ltd., Kobe University, and Nobelpharma.
There are seven hundred and thirty-three US patents protecting this investigational drug and five international patents.
Recent Clinical Trials for Arbekacin
|A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia||Meiji Seika Pharma Co., Ltd.||Phase 1|
|Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers||Meiji Seika Pharma Co., Ltd.||Phase 1|
|Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy||Japan Medical Association||Phase 2|
Top disease conditions for Arbekacin
Top clinical trial sponsors for Arbekacin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Arbekacin||Start Trial||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|Arbekacin||Start Trial||Anti-CS1 antibodies and antibody drug conjugates||AbbVie Biotherapeutics Inc. (Redwood City, CA)||Start Trial|
|Arbekacin||Start Trial||Composition including rapamycin as active ingredient for preventing or treating hearing loss||AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Suwon-si, Gyeonggi-do, KR)||Start Trial|
|Arbekacin||Start Trial||Nucleic acid vaccines||ModernaTX, Inc. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Arbekacin||European Patent Office||2528893||2030-01-29||Start Trial|
|Arbekacin||European Patent Office||3138838||2030-01-29||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|